Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Don Haut

<< Previous

Bullboard Posts

Next >>

Comment by bringon10baggeron Jan 09, 2021 11:55am

269 Views

Post# 32261271

RE:RE:RE:RE:RE:Don Haut

Dr. Haut don't beat the bushes, apparently was at AskBio only since March'20 and inked the $4B deal, $2B upfront + $2B in milestone payments with Bayer by October, at this point knowing Haut is involved Bayer will just ante up to ATE's ask....LOL.....expecting a similar arrangement with ATE, interesting to know ATE's position and to the extent of the offering entire H2S platform or just Otena.......and maybe $$$$ speak volumes!...

3burtc wrote: Of course it's not the same as an approved drug. But let's face it, it will be approved. The fact the they are willing to move the IP out of Holdings company will give nothing but confidence to shareholders and big pharma.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading